Ruti Aga’s Six-Year Ban: The Real Issue Is a Glucocorticoid, Not the ‘Steroid’ Noise

The first number I wrote in the Ruti Aga file was not a marathon time. It was 6. Two years for presence, four for tampering. The sum is clean. The classification in the early reporting is not. Methylprednisolone was described as a prohibited steroid. In the WADA Prohibited List it is a glucocorticoid, class S9, prohibited in-competition by injection, oral or rectal route. That distinction changes the legal centre of the case.

I pulled the 2026 audit from the shelf; the spine had never been cracked. That habit has stayed with me. No doping sentence leaves my desk without the sample date, the substance class and the declaration status. The Aga case is exactly why. The Athletics Integrity Unit statement gives the arithmetic, the substance and the forged prescription chain. It does not give the March race mark, the field strength or the full disqualification scope. A report that fills those gaps with mood would be inventing evidence.

Aga won a half marathon in China in March. The sample was positive. She said the methylprednisolone was for a knee injury. The prescription, according to the AIU statement, was issued by a family member posing as a doctor. The clinic did not exist. The person was not medically registered. The explanation about an old prescription pad from a former workplace was rejected by the clinic itself. Three verification failures, one document.

Methylprednisolone is not an anabolic steroid. It is an anti-inflammatory glucocorticoid. Intra-articular or peri-articular injection for knee synovitis is standard sports-medicine practice in distance runners. That makes the injury story mechanistically plausible. Plausibility is not legality. Under the current WADA List, S9 glucocorticoids are prohibited in-competition when administered by injection, oral or rectal route. A therapeutic injection given out-of-competition can still become an adverse analytical finding if residues are present in-competition.

Road racing compresses the timing problem. The in-competition window normally opens at 23:59 the day before the race. A knee injection given days earlier can be caught. The athlete then needs either a Therapeutic Use Exemption or a documented route-and-timing defence. Both require real records. A forged prescription destroys the only defence that could have worked.

The sanction arithmetic is standard. Two years for the presence violation. Four years for tampering. Six years in total. The four-year tampering period is the Code’s standard response to a fabricated document or a misleading interview. The panel did not accept a no-significant-fault reduction on the presence charge. The forged paper made that reduction almost impossible.

The central finding is simple: four of the six years are about the document, not the drug. That is the part the headline misses. A glucocorticoid case can be argued on route, timing and medical necessity. A fake prescription cannot. The moment the family member produced a document from a clinic that did not exist, the case moved from a medical dispute to an integrity dispute.

I did not discover the error. I simply refused to stop checking the column. The 2+4 arithmetic tells us what the panel accepted. It accepted the presence violation. It rejected the attempt to explain it with fabricated evidence. The six-year total is not a random act of severity. It is the sum of two separate rule breaches.

The medical-governance failure sits underneath the legal one. A 32-year-old world-class marathoner should have a credentialed team doctor, a board-registered physiotherapist and access to TUE advice. If that structure existed, the knee treatment would have been documented. The fake prescription would have been unnecessary. The AIU statement names the family member. It does not name an agent, manager or camp official. Whether the entourage was investigated is unknown.

This is where the case becomes systemic. Ethiopian and Kenyan road running runs on appearance fees, agents and training camps. A Chinese label race can be a significant share of a marathoner’s annual income. Skipping a race because of knee pain is expensive. Taking an injection is cheap. Finding a credentialed doctor is hard. The gap between individual error and structural risk sits exactly there.

The performance record is analytically secondary. The March race mark is not disclosed. The field strength is not disclosed. A win tells us the race had an elite field and an in-competition testing window. It does not tell us her form. The split times in Bhubaneswar told me more than the finish line ever did. Here even the finish time is absent, so only the testing timeline survives.

The career record that survives is the 2026 Tokyo Marathon title and three second-place finishes at World Marathon Majors. Those results make her a genuine elite marathoner. The AIU statement does not announce a blanket annulment of earlier results. Absent a finding of earlier use, the 2026 title is not automatically erased. The March race result and its prize money are very likely annulled under standard AIU practice, but the statement does not spell out the scope. That silence should be reported as silence.

At 32, a six-year ban from 10 September takes her to roughly 38. Ethiopian women’s marathon depth is extreme. A 2:18–2:20 performer is not automatically selectable even without a doping record. A 38-year-old returnee with a sanction is effectively unselectable. The ban is career-terminal in practice.

The Chinese label-race circuit now carries a different kind of scrutiny. Large appearance-fee budgets, deep East African fields and AIU testing are colliding in the same races. The appearance-fee economy and the testing economy share a start line. That collision will produce more cases. It will also produce more document checks, because the enforcement frontier has moved from the sample to the paperwork.

This is the broader shift. Anti-doping used to ask a single question: what was in the sample? The modern case asks a second question: how did the athlete explain it? Is the prescription real? Does the clinic exist? Is the doctor registered? A good lawyer cannot save an athlete who has no medical file. A bad document can bury an athlete who might have had a legitimate defence.

The mainstream read is right on one point. A forged prescription is a serious violation. It attacks the foundation of the testing system. If athletes can manufacture documents, the TUE system loses its meaning. The four-year tampering sanction is not disproportionate in the abstract. It is the standard price for attacking the integrity of the process.

The contrarian point is different. Methylprednisolone is unlikely to offer a major endurance advantage. Pain relief can allow an injured runner to compete, but that logic applies to many legal anti-inflammatories. Framing Aga as a ‘superstar doper’ is easy and inaccurate. This is mostly a document case. The athlete’s own conduct turned a defensible medical explanation into career death.

A second concession is necessary. The system failed before the athlete did. An injured marathoner with income at stake, an informal medical network and no TUE education is a predictable risk. That does not erase individual responsibility. It explains why the same failure keeps appearing in different cases. The document is downstream of an under-resourced medical structure.

A third concession cuts the other way. Four years for tampering is the global baseline. Calling the sanction uniquely harsh on African road runners misreads the rulebook. The real inequality is access to doctors, lawyers and TUE advice. The question is not whether the rule is different for Aga. The question is whether the process reaches her with the same support as a European marathoner with a full medical team.

Appeal risk is live but low-value. A CAS panel will look at the forged prescription, the non-existent clinic and the clinic’s denial. Those are document facts. The appeal window is short. The reasoned decision may clarify the disqualification scope. It is unlikely to overturn the tampering finding.

The more consequential question is the entourage. Who advised the family member? Who accepted the document? Was the agent or camp manager investigated? The AIU statement names only the family member. The Ethiopian federation response is absent. National-level TUE training, mandatory team doctors and camp medical audits are the obvious fixes. A suspension alone does not build that infrastructure.

Three sources, one timestamp, and the story finally stopped arguing with itself. The AIU statement, the WADA S9 classification and the clinic’s denial point in the same direction. The medical use of methylprednisolone was plausible. The fake paper turned it into a six-year case. The record does not care whether you read it; the reading changes you.

Ruti Aga’s 2026 Tokyo title remains part of her record. The six-year ban closes her elite career. Both facts can sit together. Sport does not require a single clean story. The next question is whether the AIU will treat the entourage as part of the case, or whether the athlete will carry the whole ledger alone.